A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/12/10/1375/19478778/12-10-1375.pdf
Reference19 articles.
1. Single-agent vinorelbine in the treatment of non-small-cell lung cancer;Wozniak;Semin Oncol,1999
2. Vinorelbine vs. vinorelbine plus cisplatin in advanced non-small-cell lung cancer: A randomized trial;Depierre;Ann Oncol,1994
3. Randomized study of vinorelbine and cisplatin vs. vindesine and cisplatin vs. vinorelbine alone in advanced non-small-cell lung cancer: Results of an European multicenter trial including 612 patients;Le Chevalier;J Clin Oncol,1994
4. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer;Crawford;J Clin Oncol,1996
5. Patient preferences for oral vs. intravenous palliative chemotherapy;Liu;J Clin Oncol,1997
Cited by 90 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study;The Breast;2024-04
2. Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-arm, Prospective Study;Cancer Research and Treatment;2023-10-12
3. Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations;Cancer Treatment Reviews;2021-11
4. Metronomic oral vinorelbine doublet chemotherapy with carboplatin in treatment of advanced lung cancer: a feasibility and safety study;F1000Research;2021-07-28
5. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03);Therapeutic Advances in Medical Oncology;2021-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3